Jerome B. Zeldis, MD, PhD; Thomas A. Depner, MD; I. K. Kuramoto, BS; Robert G. Gish, MD; Paul V. Holland, MD
The incidence of viral hepatitis in hemodialysis units has declined over the past 20 years with improved infection control strategies, including patient surveillance and segregation, plus improved prophylaxis with immune globulin, hepatitis B immune globulin, hepatitis B vaccines, and disinfectant procedures (1). Despite these measures, some hemodialysis patients have transient or prolonged elevations of their aminotransferase levels. Furthermore, end-stage liver disease is a major cause of death in long-term survivors of renal transplantation (2). Non-A, non-B hepatitis appears to be the major cause of hepatitis in hemodialysis units. Recently, a viral agent, hepatitis C virus (HCV), was isolated that may
Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The Prevalence of Hepatitis C Virus Antibodies among Hemodialysis Patients. Ann Intern Med. ;112:958–960. doi: 10.7326/0003-4819-112-12-958
Download citation file:
Published: Ann Intern Med. 1990;112(12):958-960.
Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use